Institut Godinot

At Institut Godinot in Reims, a major focus is digestive system oncology, with trials centered on colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, and biliary tract cancer. The research is largely aimed at improving treatment effectiveness, refining first-line therapy, and testing new combinations for advanced or hard-to-treat disease.

• Advanced and metastatic colorectal cancer, including biomarker-guided treatment approaches
• Gastric, gastroesophageal junction, and esophageal adenocarcinoma with new therapy strategies
• Pancreatic and biliary tract cancers, especially in advanced settings

Several studies also explore how molecular features and patient-specific factors can help tailor care, supporting more personalized treatment decisions for people with gastrointestinal cancers.

The site has a strong program in breast cancer research, covering early, locally advanced, and metastatic disease. Trials examine hormone receptor-positive, HER2-positive, and triple-negative breast cancer, with the goal of improving outcomes, reducing unnecessary treatment, and identifying better ways to prevent relapse.

• ER-positive, HER2-negative breast cancer in early and metastatic settings
• HER2-positive metastatic breast cancer and treatment de-escalation strategies
• Triple-negative breast cancer, including high-risk and brain-metastatic disease

Research at Institut Godinot also includes studies using blood-based markers such as ctDNA to guide treatment decisions and improve monitoring for recurrence.

Another major area of activity is genitourinary oncology, with trials in prostate cancer, renal cell carcinoma, and urothelial carcinoma. These studies are designed to evaluate new treatment options, compare standard approaches, and strengthen long-term disease control in advanced or recurrent disease.

• Metastatic and castration-resistant prostate cancer
• Renal cell carcinoma, including intermediate- and poor-risk disease
• Urothelial carcinoma and other advanced urinary tract cancers

The research also includes biomarker-driven studies, aiming to match patients with therapies more likely to be effective based on tumor characteristics.

The gynecologic cancer portfolio includes trials in ovarian cancer, endometrial cancer, cervical cancer, and related rare tumors such as uterine sarcoma. The main purpose is to improve survival, reduce recurrence, and test new options for patients with advanced or treatment-resistant disease.

• Ovarian and fallopian tube cancers, including recurrent and platinum-resistant disease
• Endometrial cancer, especially advanced, recurrent, or molecularly selected cases
• Cervical cancer and other female urogenital malignancies

These studies often focus on combining existing treatments in smarter ways or using molecular markers to guide therapy choices for women with complex gynecologic cancers.

Clinical research in respiratory tract diseases and head and neck cancer includes studies in non-small cell lung cancer, small cell lung cancer, and multiple squamous cell carcinomas. The emphasis is on evaluating immunotherapy, targeted therapy, and combined treatment strategies to improve disease control.

• Non-small cell lung cancer, including ROS1-positive and metastatic disease
• Small cell lung cancer, especially frail or limited-stage patients
• Head and neck squamous cell carcinoma across several anatomical sites

These trials aim to improve response rates, extend progression-free survival, and refine treatment for patients with advanced thoracic or upper aerodigestive cancers.

The site also conducts research in sarcoma, osteosarcoma, and other rare solid tumors, reflecting a strong interest in difficult-to-treat cancers with limited standard options. The studies are designed to test new therapies, compare treatment approaches, and improve outcomes in high-risk disease.

• Soft tissue sarcoma, including advanced and localized high-risk cases
• Osteosarcoma in children, adolescents, and adults
• Rare metastatic tumors and selected biomarker-defined solid cancers

Research in this area often focuses on survival, disease control after surgery, and better treatment planning for patients with uncommon cancers.

A notable theme across the research portfolio at Institut Godinot is precision oncology. Many trials use molecular markers, circulating tumor DNA, or tumor biology to identify patients who may benefit from treatment changes, de-escalation, or intensified therapy.

• ctDNA-guided treatment selection and relapse detection
• Biomarker-based approaches in breast, colorectal, and endometrial cancers
• Personalized medicine for advanced cancers with specific genetic features

This research supports more individualized cancer care by matching treatment intensity to each patient’s risk and tumor characteristics.